• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.注意差距：接受经皮血管重建术的低风险急性冠状动脉综合征中的血小板抑制
J Am Heart Assoc. 2019 Dec 3;8(23):e014498. doi: 10.1161/JAHA.119.014498. Epub 2019 Nov 26.
2
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.一项随机试验，评估三种不同糖蛋白IIb/IIIa拮抗剂对急性冠状动脉综合征患者糖蛋白IIb/IIIa血小板受体抑制及临床终点的影响。
Cardiovasc Ther. 2016 Oct;34(5):330-6. doi: 10.1111/1755-5922.12203.
3
Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.经皮冠状动脉血运重建术治疗急性冠状动脉综合征时冠状动脉内应用依替巴肽：评估血小板糖蛋白 IIb/IIIa 受体占有率和血小板功能的研究（ICE 试验）。
Circulation. 2010 Feb 16;121(6):784-91. doi: 10.1161/CIRCULATIONAHA.109.882746. Epub 2010 Feb 1.
4
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.糖蛋白IIb/IIIa抑制剂对替格瑞洛与氯吡格雷相比在急性冠脉综合征患者中的疗效和安全性的影响：来自血小板抑制和患者预后（PLATO）试验的分析
Am Heart J. 2016 Jul;177:1-8. doi: 10.1016/j.ahj.2016.03.015. Epub 2016 Apr 13.
5
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.上游氯吡格雷的使用与急性冠脉综合征患者早期依替巴肽治疗的疗效和安全性：来自非 ST 段抬高急性冠脉综合征患者早期糖蛋白 IIb/IIIa 抑制（EARLY ACS）试验的分析。
Circulation. 2011 Feb 22;123(7):722-30. doi: 10.1161/CIRCULATIONAHA.110.958041. Epub 2011 Feb 7.
6
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.替格瑞洛与氯吡格雷治疗ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗的疗效评估
J Cardiovasc Pharmacol. 2016 Aug;68(2):115-20. doi: 10.1097/FJC.0000000000000390.
7
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.急性冠状动脉综合征经皮冠状动脉介入治疗期间阿昔单抗、替罗非班和依替巴肽对血小板抑制作用的随机对照研究：COMPARE试验。阿昔单抗、瑞替普酶和依替巴肽对血小板聚集测量的比较。
Circulation. 2002 Sep 17;106(12):1470-6. doi: 10.1161/01.cir.0000029744.01096.1f.
8
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?非ST段抬高型急性冠脉综合征及经皮冠状动脉介入治疗中的血小板抑制剂：糖蛋白IIb/IIIa抑制剂、氯吡格雷，还是两者联用？
Vasc Health Risk Manag. 2006;2(1):39-48. doi: 10.2147/vhrm.2006.2.1.39.
9
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.普拉格雷联合或不联合糖蛋白IIb/IIIa抑制剂在接受经皮介入治疗的急性冠脉综合征患者中的疗效与安全性：TRITON-TIMI 38（通过优化普拉格雷血小板抑制评估治疗转归改善情况-心肌梗死溶栓试验38）分析
J Am Coll Cardiol. 2009 Aug 18;54(8):678-85. doi: 10.1016/j.jacc.2009.05.025.
10
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.糖尿病对行择期经皮冠状动脉介入治疗的肌钙蛋白阴性急性冠状动脉综合征患者替格瑞洛与氯吡格雷药效学影响的研究
J Am Heart Assoc. 2017 Mar 29;6(4):e005650. doi: 10.1161/JAHA.117.005650.

本文引用的文献

1
Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial.替格瑞洛粉碎剂与依替巴肽推注联合氯吡格雷对行经皮冠状动脉介入治疗的肌钙蛋白阴性急性冠状动脉综合征患者的影响：一项随机临床试验。
J Am Heart Assoc. 2019 Dec 3;8(23):e012844. doi: 10.1161/JAHA.119.012844. Epub 2019 Nov 26.
2
Loading with Oral P2Y12 Receptor Inhibitors: To Crush or Not to Crush?口服 P2Y12 受体抑制剂负荷剂量：粉碎还是不粉碎？
Thromb Haemost. 2019 Jul;119(7):1037-1047. doi: 10.1055/s-0039-1688790. Epub 2019 May 12.
3
The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.早期与延迟 P2Y12 抑制对 ST 段抬高型心肌梗死经皮冠状动脉介入治疗的疗效：系统评价和荟萃分析。
EuroIntervention. 2018 May 20;14(1):78-85. doi: 10.4244/EIJ-D-17-00852.
4
Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.替格瑞洛和依替巴肽推注与替格瑞洛和依替巴肽推注加 2 小时输注在接受早期经皮冠状动脉介入治疗的高危急性冠状动脉综合征患者中的比较。
J Am Heart Assoc. 2017 Jun 13;6(6):e005562. doi: 10.1161/JAHA.117.005562.
5
Effect of platelet inhibition with cangrelor during PCI on ischemic events.PCI 中用坎格瑞洛进行血小板抑制对缺血事件的影响。
N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10.
6
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.坎格雷洛和氯吡格雷的药效学作用：来自坎格雷洛与标准治疗以实现血小板抑制最佳管理（CHAMPION）试验的血小板功能子研究。
J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.
7
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.在接受经皮冠状动脉介入治疗的心肌梗死患者中，普拉格雷与替罗非班推注与短时间推注后持续输注及与普拉格雷联合应用的比较：FABOLUS PRO 试验（与替罗非班比较，在 ST 段抬高型心肌梗死患者接受负荷剂量普拉格雷治疗的基础上或替代替罗非班通过提前中断或缩短输液管路的方式来实现替格瑞洛的应用）。
JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006.
8
Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.氯吡格雷预处理与急性 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后的住院病死率降低相关。
Eur Heart J. 2011 Dec;32(23):2954-61. doi: 10.1093/eurheartj/ehr360. Epub 2011 Sep 14.
9
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.急性冠脉综合征经皮冠状动脉介入治疗后普拉格雷负荷剂量后高反应血小板与心血管事件。
J Am Coll Cardiol. 2011 Jul 26;58(5):467-73. doi: 10.1016/j.jacc.2011.04.017.
10
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.随机双盲评估替格瑞洛与氯吡格雷在稳定型冠状动脉疾病患者中的抗血小板作用的起效和失效：ONSET/OFFSET 研究。
Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.

Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.

作者信息

Sharma Ravi K, Pinto Duane S

机构信息

Cardiovascular Institute Beth Israel Deaconess Medical Center Harvard Medical School Boston MA.

出版信息

J Am Heart Assoc. 2019 Dec 3;8(23):e014498. doi: 10.1161/JAHA.119.014498. Epub 2019 Nov 26.

DOI:10.1161/JAHA.119.014498
PMID:31766972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6912963/
Abstract
摘要